ULURU Inc., founded in 1987 and headquartered in the United States, is a specialty pharmaceutical company that focuses on developing wound management and oral care products. The company is known for its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system, aiming to enhance clinical outcomes through controlled delivery.
ULURU Inc. recently received a $2.22M post-IPO equity investment as of 18 September 2023. This funding suggests a continued belief in the company's growth potential and innovative processes within the biotech sector. With its long-standing presence since 1987, ULURU Inc. operates within a niche market, leveraging its proprietary technologies to stand out in the pharmaceutical industry.
The focus on improving patient outcomes positions ULURU Inc. as a promising player for investors interested in companies that blend pharmaceutical innovation with practical consumer applications.